The biosimilar landscape is changing. Recent regulatory developments could streamline development, accelerate market entry and intensify competition for off-patent biologics. In a new PM360 Think Tank article, six indust...

Advancing an asset towards human studies but not there yet? Stop by ICON Booth \#1861 and speak with one of our drug development scientists. Learn how we approach development and how our nonclinical, CMC, and regulatory ...

When a data issue is closed, how do you know it’s really been resolved? Join Shabeeb Kannattikuni at the PHUSE Single Day Event in North Carolina, where he’ll share a SAS-based solution to checking data issue resolution...

Successful obesity trials depend on reaching and engaging the right patients. At #ObesityWeek, visit ICON at booth \#212 to explore recruitment expertise and retention-focused strategies designed to support long-term eng...

Congress participation decisions made easier. Meetings are expensive, arrangements are time consuming. With 50+ data fields to compare details, PubsHub Journals & Congresses makes your decision making faster and easier. ...

The 2028 milestone Orphan medicinal products will come under JCA rules in January 2028, with all remaining medicines following by 2030. For sponsors already in phase 2, the decisions made today could shape future Europea...

The questions facing healthcare decision-makers are becoming increasingly complex. How do we generate better evidence? Measure outcomes more effectively? Apply AI responsibly? Ensure patient perspectives are reflected? J...

ICON will attend the 19th EBF Open Symposium, taking place from 17–19 November at the Hyatt Regency Barcelona Tower. Join us at booth #B1 to meet our experts and learn how ICON delivers high-quality bioanalytical soluti...

In cell and gene therapy, the unit of supply is no longer simply a vial. It is an interconnected journey involving the patient, product, place, time, condition and decision status. At IRT & RTSM 2026, ICON’s Alyssa Gill...

Latest issue out now. Regulatory requirements continue to evolve across global markets. Keeping pace with changes from the FDA, EMA, MHRA, PMDA, NMPA and other health authorities is critical for successful product deve...

Early intervention is the most promising path forward for MASLD, and extremely difficult to execute. Without reliable methods for identifying biologically high-risk patients before symptoms emerge, early-intervention tri...

ICON is looking forward to once again attending the #OCTDACH conference on 3–4 November at the Congress Center in Basel, Switzerland. We invite you to visit us at booth \#6 to learn how we can help you navigate complex...